ITGB2 and progressive multifocal leukoencephalopathy: We believe that our integrin agonist LA1 will have a significantly lower risk of PML in patients for two reasons: (a) because it enhances CD11b/CD18-dependent cell adhesion (thus reducing risk of CD11b+ progenitors escaping into circulation, without affecting other cell types) and (b) because it primarily targets innate immune cells vs T-cells, thus may not affect migration of T-cells to fight-off JC virus, in case of its re-activation in the brain tissue.